How did health tech founders raise in 2025?

The 2025 numbers

A rising total alongside a falling deal count is the whole story of the year. Capital didn't leave the sector. It gathered behind a smaller number of companies that investors believed could build inside the health system, and everybody else competed for a thinner slice.

Where it landed, by segment: clinical workflow took $1.9B, non-clinical workflow another $1.9B, fitness and wellness $2.0B, and data infrastructure $893M. Clinical and non-clinical workflow together captured 39% of all funding, a first since Rock Health began tracking in 2011. Sitting inside the workflow was the difference between getting funded and waiting.

The AI premium, and what earns it

An 83% premium per round, and the AI-first share of funding climbed from 37% the year before to 54%. The premium is real and it is conditional. It attaches to companies where AI is core to how value gets delivered inside a clinical workflow, and investors discount cosmetic positioning fast, because they have now seen several hundred versions of the same claim.

Abridge is the clean illustration. The company turns patient-clinician conversations into structured clinical notes, which puts it inside the workflow rather than beside it. It raised a $250M Series D in February 2025 and a $300M Series E four months later at $5.3B with a16z leading. The pitch was never that they use AI. It was that they were already embedded in health systems, with the usage data to show it. Lila Sciences ran the other extreme, taking $200M seed and $235M Series A inside seven months to a $1.3B valuation on a scientific superintelligence platform story, where investors were buying the possibility of owning a category rather than revenue.

Providers became the market makers

Buyers split roughly into providers at 20%, pharma and payers at 20%, technology platforms at 16%, and a broader mix of direct-to-consumer, employers and government making up the remaining 44%. The shift underneath those numbers matters more than the split itself. Hospitals and health systems now shape what gets built, which means a VC's confidence in your company increasingly follows a provider's willingness to pilot it.

So the question your pitch has to answer early is which provider is already using this, and what happened when they did. A named system running a real pilot does more for a health tech round than any amount of model performance.

Where health tech rounds die

Most health tech founders can build the product. Many can navigate the regulatory pathway. Rounds die somewhere else, on the question of how the company makes money inside the health system.

For a US company that means the reimbursement chain: who pays, through which pathway, and whether it's the provider, the payer or the patient. For a European or rest-of-world company it means the route into the US, because that's where the revenue ceiling lifts, and every serious health tech investor asks it. Founders who closed in 2025 had this answer before their first meeting and put it near the front of the conversation. Founders who lost rounds usually had a strong demo and a vague answer here.

Underneath this is a narrative problem more than a commercial one. The framing that works is a beachhead: this specific workflow, in this specific setting, is where we prove the mechanism, because the pain there is worse than anywhere else, and here is how the same mechanism carries into the rest of the system. That turns a company an investor reads as a point solution into a platform with a sensible starting position. The general version of that move is in how to develop your spiky point of view.

What seed looks like now

A standard digital health seed runs $1M to $5M. An AI-focused one runs $5M to $15M, with the average sitting near $4.6M. Which bracket you land in tends to follow whether you can show how money flows inside the system rather than on how good the technology is.

Honey Health is the pattern at this stage: $7.8M seed, led by Pelion Health Partners, emerging from stealth with the round already done. Specialist health funds like Pelion don't back "AI for healthcare." They back teams who understand how health systems buy and implement, and Honey Health had that worked out before pitching, so the raise was largely a formality.

Two process points that separated the closers

Beyond the narrative work, two things showed up repeatedly among founders who closed in 2025.

They went to specialist health investors before generalists. A specialist fund understands the reimbursement question without being educated, and once one has validated you, generalist funds treat that as evidence. Running it the other way around means spending your best early meetings teaching people your market.

And they compressed the process. The health tech founders who closed quickly ran a three-week sprint of batched meetings rather than dripping introductions across six months. This matters more in health tech than most sectors, because diligence cycles are long, and a round that starts slowly can spend a year in motion. Getting the meetings to land together is a preparation problem you solve before launching, which I've written up in how to build an investor network before you raise.

Gian Seehra Ex-Octopus Ventures, part of deploying $200M as a VC. 3x founder, raised $16M. Has coached 120+ founders who have raised $250M+ collectively.